On Jan. 7, 2019, Fertin Pharma A/S announced that it had acquired Tab Labs Inc.
Fertin Pharma, headquartered in Vejle, Denmark, is the leading independent B2B developer and manufacturer of medicated chewing gum, primarily nicotine chewing gum used for withdrawal management in the process of tobacco cessation. Tab Labs is a full-service, private label contract manufacturer of functional tablets and chewing gum based in Vancouver, British Columbia.
Tab Labs will serve as an important bridgehead for Fertin Pharma in the large North American market for dietary supplement products delivered through innovative and convenient systems such as chewing gum, mints, lozenges and Zapliq®. Tab Labs will also provide MedCan Pharma A/S, an affiliate of Fertin Pharma, with an interesting opportunity to serve the Canadian market with edible types of Cannabinoid containing products.
Gowling WLG advised Fertin Pharma in this acquisition with a team that included Stefan McConnell (corporate/M&A), Paul Carenza (tax), Krista Schofer (employment) and Karoline Clarke (real estate), assisted by student-at-law Kean Silverthorn.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.